Literature DB >> 6506026

Assay of factor IX antigen using an enzyme immuno assay.

A Parquet-Gernez, C Mazurier, J Amiral, J L Martinoli.   

Abstract

An Enzyme Linked immuno Sorbent Assay (ELISA) was developed for the measurement of factor IX:Ag. The results obtained in 90 control subjects, 56 hemophilia B patients and 40 patients under oral anticoagulant treatment were compared with factor IX:C and factor IX:Ag levels according to Electro Immuno-Assay (EIA). In healthy volunteers the mean factor IX:C level was 106.7 U/dl, the mean factor IX:Ag level was 96.8 U/dl according to EIA procedure and 101.5 U/dl according to ELISA method. Using ELISA, 10 hemophiliacs had no detectable antigen, and 13 had minute amounts of IX:Ag. All these patients are classified as B-. Among the others 21 had reduced antigen and are considered as BR and 12 had normal level of IX:Ag and are B+. Patients taking oral anticoagulants had not only a decreased factor IX:C level but also a reduced factor IX:Ag level which is always lower when using EIA procedure in the presence of EDTA than according to ELISA method.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6506026     DOI: 10.1016/0049-3848(84)90273-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  2 in total

1.  Missense mutations and the magnitude of functional deficit: the example of factor IX.

Authors:  S S Sommer; E J Bowie; R P Ketterling; C D Bottema
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

2.  T296----M, a common mutation causing mild hemophilia B in the Amish and others: founder effect, variability in factor IX activity assays, and rapid carrier detection.

Authors:  R P Ketterling; C D Bottema; D D Koeberl; S Ii; S S Sommer
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.